Breaking News, Financial News

1Q Financial Report: Wyeth

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Wyeth 1Q Revenues: $4.8 billion (+6%) 1Q Earnings: $1.1 billion (+13%) Comments: Enbrel, Effexor, Prevnar, Premarin and Protonix drove revenue growth in the quarter. The company has rights to Enbrel outside of the U.S. and Canada where net revenue was $335 million for the quarter, up 42%. Effexor sales were $945 million, up 9%. Prevnar sales were up 10% to $432 million. Premarin product sales were $266 million for the quarter, up 26%. Protonix sales were $482 million, up 18%. R&...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters